fda bpc 157 compounding category 2 list 1 vs. Category 2. The FDA's peptide update, explained. Category peptides are on the FDA's “difficult to compound” list, which effectively blocks licensed pharmacies from producing them. Category 1 means FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 Industry Update: Interim 503A and 503B Bulks Lists New Revisions Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



